Torray Investment Partners LLC Has $2.66 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Torray Investment Partners LLC grew its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 55,611 shares of the biopharmaceutical company’s stock after purchasing an additional 353 shares during the period. Torray Investment Partners LLC’s holdings in Halozyme Therapeutics were worth $2,659,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. increased its position in Halozyme Therapeutics by 0.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company’s stock worth $85,254,000 after purchasing an additional 9,780 shares during the last quarter. Unified Investment Management acquired a new position in Halozyme Therapeutics in the 4th quarter worth about $895,000. Smartleaf Asset Management LLC increased its position in Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 197 shares during the last quarter. Fisher Asset Management LLC increased its position in Halozyme Therapeutics by 28.0% in the 4th quarter. Fisher Asset Management LLC now owns 414,719 shares of the biopharmaceutical company’s stock worth $19,828,000 after purchasing an additional 90,714 shares during the last quarter. Finally, Parkside Financial Bank & Trust increased its position in Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 322 shares during the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Performance

HALO opened at $57.96 on Tuesday. The firm has a market capitalization of $7.14 billion, a P/E ratio of 16.90, a price-to-earnings-growth ratio of 0.42 and a beta of 1.25. The stock’s 50 day moving average price is $54.53 and its two-hundred day moving average price is $54.72. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a 12-month low of $37.73 and a 12-month high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. The firm had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. On average, equities analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 1,697 shares of the firm’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the sale, the senior vice president now owns 173,756 shares in the company, valued at approximately $10,126,499.68. This trade represents a 0.97 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey William Henderson sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $58.69, for a total value of $293,450.00. Following the completion of the sale, the director now owns 33,611 shares of the company’s stock, valued at $1,972,629.59. This represents a 12.95 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 31,697 shares of company stock worth $1,754,451. 2.40% of the stock is currently owned by company insiders.

Analyst Ratings Changes

HALO has been the topic of a number of analyst reports. Piper Sandler increased their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Wells Fargo & Company lowered their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. HC Wainwright increased their price objective on Halozyme Therapeutics from $70.00 to $72.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Finally, Benchmark reissued a “buy” rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $62.78.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.